Novel TSHB variant (c.217A>C) causing severe central hypothyroidism and pituitary hyperplasia

Adam I Kaplan; Catherine Luxford; Roderick J Clifton-Bligh

doi:10.1530/EDM-22-0230

Novel TSHB variant (c.217A>C) causing severe central hypothyroidism and pituitary hyperplasia

Endocrinol Diabetes Metab Case Rep. 2022 Aug 1:2022:22-0230. doi: 10.1530/EDM-22-0230. Online ahead of print.

Authors

Adam I Kaplan^{1

2}, Catherine Luxford^{1

3}, Roderick J Clifton-Bligh^{1

2

3}

Affiliations

¹ Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
² Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.
³ Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia.

Abstract

Summary: Biallelic pathological variants in the thyroid stimulating hormone (TSH) subunit β gene (TSHB) result in isolated TSH deficiency and secondary hypothyroidism, a rare form of central congenital hypothyroidism (CCH), with an estimated incidence of 1 in 65 000 births. It is characterised by low levels of free thyroxine and inappropriately low serum TSH and may therefore be missed on routine neonatal screening for hypothyroidism, which relies on elevated TSH. We describe a patient with CCH who developed recurrence of pituitary hyperplasia and symptomatic hypothyroidism due to poor compliance with thyroxine replacement. She was diagnosed with CCH as a neonate and had previously required trans-sphenoidal hypophysectomy surgery for pituitary hyperplasia associated with threatened chiasmal compression at 17 years of age due to variable adherence to thyroxine replacement. Genetic testing of TSHB identified compound heterozygosity with novel variant c.217A>C, p.(Thr73Pro), and a previously reported variant c.373delT, p.(Cys125Valfs*10). Continued variable adherence to treatment as an adult resulted in recurrence of significant pituitary hyperplasia, which subsequently resolved with improved compliance without the need for additional medications or repeat surgery. This case describes a novel TSHB variant associated with CCH and demonstrates the importance of consistent compliance with thyroxine replacement to treat hypothyroidism and prevent pituitary hyperplasia in central hypothyroidism.

Learning points: Pathogenic variants in the TSH subunit β gene (TSHB) are rare causes of central congenital hypothyroidism (CCH). c.217A>C, p.(Thr73Pro), is a novel TSHB variant, presented in association with CCH in this case report. Thyroxine replacement is critical to prevent clinical hypothyroidism and pituitary hyperplasia. Pituitary hyperplasia can recur post-surgery if adherence to thyroxine replacement is not maintained. Pituitary hyperplasia can dramatically reverse if compliance with thyroxine replacement is improved to maintain free thyroxine (FT4) levels in the middle-to-upper normal range, without the need for additional medications or surgeries.